Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Non-cardioselective b-blockers (beta-blockers). |
| Generic Name : | Propranolol - hypertension/thyroid/ phaeochromocytoma |
| Drug description : | Inderal LA: 160 mg lavender/pink sustained-release capsules marked INDERAL LA. Half-Inderal LA: 80 mg lavender/ pink sustained-release capsules marked HALF-INDERAL LA. Inderal Tablets: pink f-c tablets marked with tablet name and strength. |
| Presentation : | Inderal LA: Propranolol hydrochloride 160mg . Half-Inderal LA: Propranolol hydrochloride 80mg . Inderal Tablets: Propranolol hydrochloride 10 mg , 40 mg , 80 mg . |
| Indications : | Inderal LA and Half-Inderal LA: Hypertension. Adjunct in thyrotoxicosis. Inderal Tablets: As above and phaeochromocytoma. |
| Adult Dosage : | Inderal LA and Half-Inderal LA: Hypertension, 160 mg daily increasing if necessary in 80 mg increments until adequate response is achieved. Thyrotoxicosis, 80 mg or 160 mg daily; maximum 240 mg daily. Inderal Tablets: Hypertension, initially 80 mg twice daily increasing if necessary at weekly intervals to 160 - 320 mg daily. Phaeochromocytoma, 60 mg daily with an a-blocker for 3 days preoperatively or 30 mg daily in inoperable cases. Thyrotoxicosis, 10-40mg three to four times daily. |
| Child Dosage : | Inderal LA and Half-Inderal LA: Not recommended. Inderal Tablets: Phaeochromocytoma, thyrotoxicosis, 0.25 - 0.5 mg/kg body-weight three or four times daily. |
| Contra Indications : | 2nd or 3rd degree AV block, sinus bradycardia, sick sinus syndrome, peripheral arterial disease, uncompensated cardiac failure, cardiogenic shock, hypotension, untreated phaechromocytoma. Generally contra-indicated in patients with obstructive airways disease or a history of bronchospasm. Known hypersensitivity. Prinzmetal's angina. Metabolic acidosis. |
| Special Precautions : | Poor cardiac reserve should be controlled with digitalis and diuretics. First degree AV block, portal hypertension. Diabetes; metabolic acidosis. Asthenic symptoms. Cerebrovascular insufficiency. Renal or hepatic impairment, thyrotoxicosis. General anaesthesia; consider withdrawal before elective surgery. Pregnancy, lactation. Withdraw gradually. |
| Interactions : | Clonidine withdrawal, verapamil, diltiazem, class II calcium antagonists, class I antiarrhythmics, cardiac depressant anaesthetics, hypoglycaemics, reserpine, other antihypertensives, ergot alkaloids, cimetidine, warfarin, CNS depressants, sympathominetics, indometacin (indomethacin), ibuprofen, chlorpromazine. Refer to Summary of Product Characteristics. |
| Adverse Reactions : | Cold extremities, sleep disturbances, bradycardia, bronchospasm, heart failure deterioration, postural hypotension, GI upset, alopecia, precipitation of heart block, exacerbation of intermittent claudication, Raynaud's phenomenon, confusion, dizziness, mood changes, nightmares, psychoses and hallucinations, purpura, thrombocytopenia, dry eyes, psoriasiform skin reactions, exacerbation of psoriasis, skin rashes, paraesthesia, visual disturbances, fatigue and/or lassitude, increase in antinuclear antibodies. |
| Manufacturer : | AstraZeneca |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org